---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-297530"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2022-12-02T23:59:59+00:00"
generated_at: "2026-06-21T10:12:53.823302+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Karyopharm amends bylaws for universal proxy rules and meeting procedures

## Summary
- Eliminated requirement to make stockholder list available during meetings.
- Addressed adjournment of stockholder meetings due to technical failure in remote communication.
- Enhanced disclosure and representation requirements for shareholder nominations under universal proxy rules.
- Requires stockholders soliciting proxies to provide evidence of Rule 14a-19 compliance five business days before meeting.
- Non-compliance with Rule 14a-19 will cause Company to disregard nominations and votes for those nominees.

## SEC filing metadata
- accession: 0001193125-22-297530
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2022-12-02T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312522297530/0001193125-22-297530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312522297530/d423713d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-297530
- JSON: https://secwatch.observer/filing/0001193125-22-297530.json
- Plain text: https://secwatch.observer/filing/0001193125-22-297530.txt

## Key facts
- Governance Changes
  Karyopharm Therapeutics Inc.: The Board approved and restated the Third Amended and Restated By-Laws, effective immediately, with amendments including elimination of stockholder list requirement during meetings, addressing remote meeting adjournment due to technical failure, and revising procedural mechanics for shareholder nomi (effective 2022-12-01).
  - Change: bylaw amendment
  - Effective: 2022-12-01
  source text: On December 1, 2022, the board of directors (the “Board”) of Karyopharm Therapeutics Inc. (the “Company”) approved an amendment and restatement of the Company’s Second Amended and Restated By-Laws, as amended (as so amended and restated, the “Third Amended and Restated By-Laws”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312522297530/0001193125-22-297530-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.